Dalrada Financial Corporation’s Wholly-Owned Subsidiary, Genefic, Inc. Announces New Telemedicine Services, Enters Booming Weight Loss Drug Market
The pharmaceutical subsidiary plans on capturing a large portion of a growing market with an innovative prescription method.
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) — Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada,” “the Company”), announced today that its wholly-owned healthcare subsidiary, Genefic, Inc. (“Genefic”), has added a telemedicine service to its specialty pharmacy, allowing Genefic to efficiently offer clients direct access to its pharmaceuticals, including access to Genefic’s own weight loss drug, as the subsidiary enters the world’s booming weight loss drug market.
Related news for (DFCO)
- CEO of Dalrada Financial Corporation Subsidiary, Genefic, Inc. Discusses Revenue Drivers and Growth in New Interview
- Dalrada’s Brian Bonar Wins San Diego Business Journal’s CEO of the Year
- Dalrada Financial Corporation CEO Discusses Increased Corporate Momentum and Shares Company Updates in New Interview
- Dalrada Financial Corporation Joins Minority Business RoundTable, Accelerates Government and Private Contract Opportunities
- Dalrada Financial Corporation Healthcare Subsidiary, Genefic, Inc., Acquires IV Services Infusion Pharmacy